Literature DB >> 19705049

A pilot case-control study on the alveolar bone density measurement in risk assessment for bisphosphonate-related osteonecrosis of the jaw.

Y Takaishi1, T Ikeo, M Nakajima, T Miki, T Fujita.   

Abstract

UNLABELLED: Alveolar bone mineral density (BMD) measured by radiography standardized by aluminum step wedge pasted on the film and digitized by a computer system was significantly higher around osteonecrosis lesions than in control cases in a pilot case-control study. High alveolar bone density appears useful as a local risk factor for bisphosphonate-related osteonecrosis of the jaw (BRONJ).
INTRODUCTION: In an attempt to find a reliable test method predicting the occurrence of BRONJ in addition to various risk factors suggested, an increase of alveolar bone density near the necrotic lesions was found by computerized radiogrammetry using dental films pasted with an aluminum step wedge (Bone Right, Dentalgraphic.Com Company, Himeji) in six cases of BRONJ.
METHODS: The bone mineral density surrounding the osteonecrosis lesions showed distinctly higher density in BRONJ cases compared with age-matched controls. In one subject on bisphosphonate treatment in whom two extractions were simultaneously carried out, BRONJ occurred only at the location with extremely high alveolar bone density, but not at the other site with normal density.
CONCLUSION: This method may be useful in detecting a rise of alveolar BMD frequently occurring near the necrotic lesion in subjects with impending risk for BRONJ.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705049      PMCID: PMC2846278          DOI: 10.1007/s00198-009-1021-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  5 in total

1.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

Authors: 
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

2.  Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.

Authors:  Vassiliki M Cartsos; Shao Zhu; Athanasios I Zavras
Journal:  J Am Dent Assoc       Date:  2008-01       Impact factor: 3.634

3.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

4.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

5.  Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4- to 5-year follow-up of four patients.

Authors:  Y Takaishi; T Ikeo; T Miki; Y Nishizawa; H Morii
Journal:  J Int Med Res       Date:  2003 Nov-Dec       Impact factor: 1.671

  5 in total
  10 in total

Review 1.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

2.  Alveolar density measurement and bisphosphonate-related osteonecrosis of the jaws.

Authors:  A Taguchi
Journal:  Osteoporos Int       Date:  2009-10-27       Impact factor: 4.507

3.  Osseous changes in patients with medication-related osteonecrosis of the jaws.

Authors:  Zeynep Burcin Gönen; Canay Yillmaz Asan; Gökmen Zararsiz; Erdem Kiliç; Alper Alkan
Journal:  Dentomaxillofac Radiol       Date:  2017-11-01       Impact factor: 2.419

4.  Radiographic evidence of treatment with bisphosphonates.

Authors:  M L T Thayer
Journal:  Br Dent J       Date:  2017-04-07       Impact factor: 1.626

5.  Molecular alterations of bone quality in sequesters of bisphosphonates-related osteonecrosis of the jaws.

Authors:  C Olejnik; G Falgayrac; A During; M H Vieillard; J M Maes; B Cortet; G Penel
Journal:  Osteoporos Int       Date:  2013-10-01       Impact factor: 4.507

6.  Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.

Authors:  Kazuhito Tohashi; Motoki Nakabayashi; Isamu Kodani; Kazunori Kidani; Kazuo Ryoke
Journal:  Yonago Acta Med       Date:  2016-04-01       Impact factor: 1.641

Review 7.  Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.

Authors:  Pongsapak Wongratwanich; Kiichi Shimabukuro; Masaru Konishi; Toshikazu Nagasaki; Masahiko Ohtsuka; Yoshikazu Suei; Takashi Nakamoto; Rinus G Verdonschot; Tomohiko Kanesaki; Pipop Sutthiprapaporn; Naoya Kakimoto
Journal:  Dentomaxillofac Radiol       Date:  2021-01-15       Impact factor: 3.525

8.  What Does Bone Corticalization around Dental Implants Mean in Light of Ten Years of Follow-Up?

Authors:  Marcin Kozakiewicz; Małgorzata Skorupska; Tomasz Wach
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

9.  Assessment of alveolar bone mineral density as a predictor of lumbar fracture probability.

Authors:  Yoshitomo Takaishi; Seizaburo Arita; Mitsugi Honda; Takeshi Sugishita; Aiko Kamada; Takashi Ikeo; Takami Miki; Takuo Fujita
Journal:  Adv Ther       Date:  2013-05-15       Impact factor: 3.845

Review 10.  Imaging findings of bisphosphonate-related osteonecrosis of the jaws: a critical review of the quantitative studies.

Authors:  André Ferreira Leite; Fernanda Dos Santos Ogata; Nilce Santos de Melo; Paulo Tadeu de Souza Figueiredo
Journal:  Int J Dent       Date:  2014-06-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.